New antituberculosis drugs, regimens, and adjunct therapies: Needs, advances, and future prospects

The Lancet Infectious Diseases

Volumn 14, Issue 4, 2014, Pages 327-340

  Zumla, Alimuddin I ^a,b   Gillespie, Stephen H ^c   Hoelscher, Michael ^d,e   Philips, Patrick P J ^a   Cole, Stewart T ^f   Abubakar, Ibrahim ^a   McHugh, Timothy D ^a   Schito, Marco ^g   Maeurer, Markus ^h   Nunn, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d UNIVERSITY OF MUNICH   (Germany)

^e German Center for Infection Research   (Germany)

^f EPFL   (Switzerland)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; 7 (7 AMINO 7 METHYL 5 AZASPIRO[2.4]HEPTAN 5 YL) 6 FLUORO 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; ALANINE AMINOTRANSFERASE; AMINOSALICYLIC ACID; BEDAQUILINE; CLOFAZIMINE; CYCLOPEPTIDE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

BACTERICIDAL ACTIVITY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LATENT TUBERCULOSIS; MEDICATION COMPLIANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STREPTOMYCES GRISEUS; TREATMENT DURATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; MEDICATION ADHERENCE; RESEARCH DESIGN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84896455574     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70328-1     Document Type: Review

References (118)

1. TB-a global emergency. WHO Press Release: WHO/31 1993, WHO, World Health Organization, Geneva.
2. Global Tuberculosis report 2013. WHO/HTM/TB/2013 WHO, (accessed Nov 12, 2013). http://www.who.int/tb/publications/global_report/en.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013, 42:169-179. for the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.
4. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42:156-168. for the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.
5. Schatz A, Bugie E, Waksman SA Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 1944, 55:66-69.
6. Wassersug JD Pulmonary tuberculosis. N Engl J Med 1946, 235:220-229.
7. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ 1948, 2:769-782. Medical Research Council.
8. Fox W, Sutherland I, Daniels M A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q J Med 1954, 23:347-366.
9. Nunn AJ, Jindani A, Enarson DA Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis 2011, 15:741-745. for the Study A investigators.
10. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet 1974, 2:237-240. East African/British Medical Research Councils.
11. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972, 1:1079-1085. East African/British Medical Research Councils.
12. Treatment of tuberculosis guidelines 2010, WHO, World Health Organization, Geneva, (accessed Dec 18, 2013). http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf, 4th edition.
13. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update 2011, WHO, World Health Organization, Geneva, (accessed Jan 12, 2014). http://www.ncbi.nlm.nih.gov/books/NBK148644/.
14. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
15. Garton NJ, Christensen H, Minnikin DE, Adegbola RA, Barer MR Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002, 148:2951-2958.
16. Wayne LG, Hayes LG An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996, 64:2062-2069.
17. Loebel RO, Shorr E, Richardson HB The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 1933, 26:167-200.
18. Shleeva MO, Kudykina YK, Vostroknutova GN, Suzina NE, Mulyukin AL, Kaprelyants AS Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Tuberculosis (Edinb) 2011, 91:146-154.
19. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010, 181:174-180.
20. Zhang Y, Yew WW, Barer MR Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 2012, 56:2223-2230.
21. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, 13:529-539.
22. Zumla A, Raviglione M, Hafner R, von Reyn CF Tuberculosis. N Engl J Med 2013, 368:745-755.
23. Zumla A, Nahid P, Cole ST Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
24. McIlleron H, Meintjes G, Burman WJ, Maartens G Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007, 196(suppl):S63-S75.
25. Sudre P, ten Dam G, Kochi A Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992, 70:149-159.
26. Zumla A, Atun R, Maeurer M, et al. Viewpoint: scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 2011, 16:79-83.
27. Walter ND, Painter J, Parker M, et al. Persistent latent tuberculosis reactivation risk in us immigrants. Am J Respir Crit Care Med 2014, 189:88-95. for the TB Epidemiologic Studies Consortium.
28. Lechartier B, Rybniker J, Zumla A, Cole S Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med 2014, published online Jan 8. 10.1002/emmm.201201772.
29. Barry CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
30. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013, 42:785-801. for the European Forum for TB Innovation.
31. Amaral L, Udwadia Z, Abbate E, van Soolingen D The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012, 16:1706-1708.
32. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, et al. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother 2013, 57:5870-5877.
33. Mullin S, Mani N, Grossman TH Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother 2004, 48:4171-4176.
34. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
35. Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009, 324:801-804.
36. Pethe K, Bifani P, Jang J, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 2013, 19:1157-1160.
37. Upton AM. TBA-354: a next generation nitroimidazole for treatment of drug sensitive and drug-resistant tuberculosis. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy: San Francisco, CA, USA; Sept 9-12, 2012. 438.
38. Lechartier B, Hartkoorn RC, Cole ST In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012, 56:5790-5793.
39. Fortún J, Martín-Dávila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005, 56:180-185.
40. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013, 62:1-12. CDC.
41. European Medicines Agency positive opinion granting a conditional marketing authorisation for Deltyba EMA, (accessed Jan 12, 2014). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002552/smops/Positive/human_smop_000572.jsp&mid=WC0b01ac058001d127.
42. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-27.
43. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
44. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010, 54:3402-3407.
45. Jindani A, Hatherill M, Charalambous S, et al. A multicentre randomized clinical trial to evaluate high-dose rifapentine with a quinolone for treatment of pulmonary TB: The RIFAQUIN Trial. 20th Conference on Retroviruses and Opportunistic Infections: Atlanta, GA, USA; March 3-6, 2013. 48012.
46. Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 2013, 8:e67030.
47. Merle CS, Sismanidis C, Bah Sow O, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project. Trials 2012, 13:61.
48. Merle C, Fielding K, Lapujade O, et al., for OFLOTUB/gatifloxacin for TB Project. A randomised controlled trial of 4-month gatifloxacin-containing regimen vs. standard 6-month regimen for treating drug-susceptible pulmonary tuberculosis: main efficacy and safety results of the OLFOTUB Trial. 44th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease: Paris, France; Oct 30-Nov 3, 2013.
49. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K The challenge of new drug discovery for tuberculosis. Nature 2011, 469:483-490.
50. Zhang D, Lu Y, Liu K, et al. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J Med Chem 2012, 55:8409-8417.
51. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012, 40:1430-1442.
52. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 2010, 1:e00139. 10.
53. Wallis RS, Diacon AH, Dawson R, et al. Safety, tolerability and early bactericidal activity in sputum of PNU-100480 (sutezolid) in patients with pulmonary tuberculosis. XIX International AIDS Conference: Washington, DC, USA; July 22-27, 2012. THLBB02.
54. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, Blanchard JS Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323:1215-1218.
55. Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026. Drugs R D 2008, 9:115-124.
56. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405.
57. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012, 56:3271-3276.
58. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011, 15:949-954.
59. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
60. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013, 41:1393-1400.
61. van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment?. Clin Infect Dis 2011, 52:e194-e199.
62. Boeree M, Diacon A, Dawson R, et al. What is the "right" dose of rifampin? 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, USA; March 3-6, 2013. 148LB.
63. Fattorini L, Piccaro G, Mustazzolu A, Giannoni F Targeting dormant bacilli to fight tuberculosis. Mediterr J Hematol Infect Dis 2013, 5:e2013072.
64. Deb C, Lee C-M, Dubey VS, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 2009, 4:e6077.
65. Hu YM, Butcher PD, Sole K, Mitchison DA, Coates AR Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett 1998, 158:139-145.
66. Mak PA, Rao SP, Ping Tan M, et al. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol 2012, 7:1190-1197.
67. Bryk R, Arango N, Maksymiuk C, et al. Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase. Biochemistry 2013, 52:9375-9384.
68. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966.
69. Manca C, Koo MS, Peixoto B, Fallows D, Kaplan G, Subbian S Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS One 2013, 8:e74082.
70. Jindani A, Nunn AJ, Enarson DA Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004, 364:1244-1251.
71. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 1989, 139:871-876. Hong Kong Chest Service, Tuberculosis Research CentreTuberculosis Research Centre, MadrasMadras, British Medical Research CouncilBritish Medical Research Council.
72. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009, 180:558-563.
73. Ziganshina LE, Titarenko AF, Davies GR Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 2013, 6. CD004795.
74. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB). NCT00864383 REMox, (accessed Dec 1, 2013). http://clinicaltrials.gov/ct2/show/NCT00864383.
75. Prieto-Merino D, Smeeth L, Staa TP, Roberts I Dangers of non-specific composite outcome measures in clinical trials. BMJ 2013, 347:f6782.
76. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001, 45:3482-3486.
77. Wallis RS, Wang C, Meyer D, Thomas N Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013, 8:e71116.
78. Phillips PP, Fielding K, Nunn AJ An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 2013, 8:e63840.
79. Phillips PPJ, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012, 205(suppl):S250-S257.
80. Nunn AJ, Phillips PPJ, Gillespie SH Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis 2008, 88(suppl):S85-S92.
81. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
82. Aber VR, Nunn AJ Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 1978, 53:276-280.
83. Kayigire XA, Friedrich SO, Venter A, et al. Direct comparison of Xpert MTB/RIF with liquid and solid mycobacterial culture for the quantification of early bactericidal activity. J Clin Microbiol 2013, 51:1894-1898.
84. Bark CM, Gitta P, Ogwang S, et al. Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment. Int J Tuberc Lung Dis 2013, 17:1448-1451.
85. Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 2013, 13:362-372.
86. Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Resp Med 2013, 1:462-470.
87. Hellyer TJ, DesJardin LE, Hehman GL, Cave MD, Eisenach KD Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis. J Clin Microbiol 1999, 37:290-295.
88. Liu J-Y, Jin L, Zhao M-Y, et al. New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2011, 49:1727-1733.
89. Honeyborne I, McHugh TD, Phillips PPJ, et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol 2011, 49:3905-3911.
90. Bratton DJ, Phillips PP, Parmar MK A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC Med Res Methodol 2013, 13:139.
91. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013, 42:252-271.
92. Charalambous S, Grant AD, Moloi V, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008, 12:942-948.
93. Glynn JR, Murray J, Bester A, et al. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis 2010, 201:704-711.
94. Bryant JM, Harris SR, Parkhill J, et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Infect Dis 2013, 1:786-792.
95. Lawn SD, Harries AD, Wood R Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010, 5:18-26.
96. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
97. Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481. for the CAMELIA (ANRS 1295-CIPRA KH001) Study Team.
98. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491. for the AIDS Clinical Trials Group Study A5221.
99. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012, 60:377-383. for the TIME Study Team.
100. Antiretroviral therapy for HIV infection in adults and adolescents 2010 revision 2010, WHO, World Health Organization, Geneva, (accessed Dec 8, 2013). http://www.who.int/hiv/pub/arv/adult2010/.
101. An evaluation of the impact of early initiation of highly active anti-retroviral therapy (HAART) on tuberculosis (TB) treatment outcomes for TB patients co-infected with human immunodeficiency virus (HIV). ISRCTN77861053 TB, HAART, (accessed Dec 8, 2013). http://www.controlled-trials.com/ISRCTN77861053.
102. Skrahin A, Ahmed R, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Resp Med 2014, 2:108-122.
103. Zumla A, Maeurer M Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. J Infect Dis 2012, 205(suppl):S335-S339.
104. Upadhyay P Tuberculosis vaccine trials. Lancet 2013, 381:2253-2254.
105. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
106. Wallis RS Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am 2011, 25:895-910.
107. Lin PL, Flynn JL Understanding latent tuberculosis: a moving target. J Immunol 2010, 185:15-22.
108. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292:156-163.
109. Brodin P, Valentini D, Uhlin M, Mattsson J, Zumla A, Maeurer MJ Systems level immune response analysis and personalized medicine. Expert Rev Clin Immunol 2013, 9:307-317.
110. Casali N, Nikolayevskyy V, Balabanova Y, et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 2012, 22:735-745.
111. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208:199-202.
112. Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013, 3:e002672.
113. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014, 58:574-576.
114. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013, 188:600-607.
115. Maiga M, Ammerman NC, Maiga MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013, 208:512-519.
116. Zumla A, Atun R, Maeurer M, et al. Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs. J Infect Dis 2012, 205(suppl):S141-S146.
117. Wallis RS Sustainable tuberculosis drug development. Clin Infect Dis 2013, 56:106-113.
118. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012, 205(suppl):S228-S240.